Hong Li

Ms. Hong Li

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
BHBangxing Hong
Bangxing Hong
HLHong Li
Hong Li
YLYong Lu
Yong Lu
MZMingjun Zhang
Mingjun Zhang
YZYuhuan Zheng
Yuhuan Zheng
QYQing Yi
Qing Yi
Interferon (IFN)-γ-mediated immune response plays an important role in tumor immunosurveillance. However, the regulation of IFN-γ-mediated tumorigenesis and immune response remains elusive. USP18, an interferon stimulating response element, regulates IFN-α-mediated signaling in anti-viral immune response, but its role in IFN-γ-mediated tumorigenesis and anti-tumor immune response is unknown. In this study, USP18 in tumorigenesis and anti-tumor immune response was comprehensively appraised in vivo by overexpression or downregulation its expression in murine B16 melanoma tumor model in immunocompetent and immunodeficient mice. Ectopic expression or downregulation of USP18 in B16 melanoma tumor cells inhibited or promoted tumorigenesis, respectively, in immunocompetent mice. USP18 expression in B16 melanoma tumor cells regulated IFN-γ-mediated immunoediting, including upregulating MHC class-I expression, reducing tumor cell-mediated inhibition of T cell proliferation and activation, and suppressing PD-1 expression in CD4+ and CD8+ T cells in tumor-bearing mice. USP18 expression in B16 melanoma tumor cells also enhanced CTL activity during adoptive immunotherapy by prolonging the persistence and enhancing the activity of adoptively transferred CTLs and by reducing CTL exhaustion in the tumor microenvironment. Mechanistic studies demonstrated that USP18 suppressed tumor cell-mediated immune inhibition by activating T cells, inhibiting T-cell exhaustion, and reducing dendritic cell tolerance, thus sensitizing tumor cells to immunosurveillance and immunotherapy. These findings suggest that stimulating USP18 is a feasible approach to induce B16 melanoma specific immune response.

31 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ABAddison E. Barnett
Addison E. Barnett
Ahmad OzairAhmad Ozair
Ahmad Ozair
ABAnas S. Bamashmos
Anas S. Bamashmos
HLHong Li
Hong Li
DBDavid Bosler
David Bosler
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Introduction: Sex differences in glioblastoma (GBM) have been observed in incidence, genetic and epigenetic alterations, and immune response. These differences have extended to the methylation of the MGMT promoter, which critically impacts temozolomide resistance. However, the association between sex, MGMT methylation, and survival is poorly understood, which this study sought to evaluate. Methods: A retrospective cohort study was conducted and reported following STROBE guidelines, based on adults with newly diagnosed GBM who received their first surgical intervention at Cleveland Clinic (Ohio, USA) between 2012 and 2018. Kaplan–Meier and multivariable Cox proportional hazards models were used to analyze the association between sex and MGMT promoter methylation status on overall survival (OS). MGMT was defined as methylated if the mean of CpG 1-5 ≥ 12. Propensity score matching was performed on a subset of patients to evaluate the effect of individual CpG site methylation. Results: A total of 464 patients had documented MGMT methylation status with a mean age of 63.4 (range 19–93) years. A total of 170 (36.6%) were female, and 133 (28.7%) received gross total resection as a first intervention. A total of 42.5% were MGMT methylated, with females more often having MGMT methylation than males (52.1% vs. 37.4%, p = 0.004). In univariable analysis, OS was significantly longer for MGMT promoter methylated than un-methylated groups for females (2 yr: 36.8% vs. 11.1%; median: 18.7 vs. 9.5 months; p = 0.001) but not for males (2 yr: 24.3% vs. 12.2%; median: 12.4 vs. 11.3 months; p = 0.22, p for MGMT–sex interaction = 0.02). In multivariable analysis, MGMT un-methylated versus methylated promoter females (2.07; 95% CI, 1.45–2.95; p < 0.0001) and males (1.51; 95% CI, 1.14–2.00; p = 0.004) had worse OS. Within the MGMT promoter methylated group, males had significantly worse OS than females (1.42; 95% CI: 1.01–1.99; p = 0.04). Amongst patients with data on MGMT CpG promoter site methylation values (n = 304), the median (IQR) of CpG mean methylation was 3.0% (2.0, 30.5). Females had greater mean CpG methylation than males (11.0 vs. 3.0, p < 0.002) and higher per-site CpG methylation with a significant difference at CPG 1, 2, and 4 (p < 0.008). After propensity score matching, females maintained a significant survival benefit (18.7 vs. 10.0 months, p = 0.004) compared to males (13.0 vs. 13.6 months, p = 0.76), and the pattern of difference was significant (P for CpG–sex interaction = 0.03). Conclusions: In this study, females had higher mean and individual CpG site methylation and received a greater PFS and OS benefit by MGMT methylation that was not seen in males despite equal degrees of CpG methylation.

11 August 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
BHBetty K. Hamilton
Betty K. Hamilton
LRLisa A. Rybicki
Lisa A. Rybicki
HLHong Li
Hong Li
TLTaylor Lucas
Taylor Lucas
DCDonna Corrigan
Donna Corrigan
NMNavneet S. Majhail
Navneet S. Majhail
Tacrolimus (Tac)/methotrexate (MTX) is standard graft-versus-host disease (GVHD) prophylaxis; however, is associated with several toxicities. Tac, reduced-dose MTX (mini-MTX), and mycophenolate mofetil (MMF) have been used but never compared with standard MTX. We performed a randomized trial comparing Tac/MTX (full-MTX) with Tac/mini-MTX/MMF (mini-MTX/MMF) for GVHD prevention after allogeneic hematopoietic cell transplantation (HCT). Patients (pts) receiving first myeloablative HCT using an 8/8 HLA-matched donor were eligible. Primary end points were incidence of acute GVHD (aGVHD), mucositis, and engraftment. Secondary end points included chronic GVHD (cGVHD), organ toxicity, infection, relapse, nonrelapse mortality (NRM), and overall survival (OS). Ninety-six pts were randomly assigned to full-MTX (N = 49) or mini-MTX (N = 47). The majority (86%) used bone marrow grafts. There was no significant difference in grade 2-4 aGVHD (28% mini-MTX/MMF vs 27% full-MTX; P = .41); however higher incidence of grade 3-4 aGVHD (13% vs 4%; P = .07) with mini-MTX/MMF. Pts receiving mini-MTX/MMF had lower grade 3 or 4 mucositis and faster engraftment. There were no differences in moderate-to-severe cGVHD at 1 year or infections. Pts receiving mini-MTX/MMF experienced less nephrotoxicity and respiratory failure. There was no difference in the 1-year relapse (19% vs 21%; P = .89) and OS (72% vs 71%; P = .08), and mini-MTX/MMF was associated with lower but nonsignificant NRM (11% vs 22%; P = .06). Compared with full-MTX, mini-MTX/MMF was associated with no difference in grade 2-4 aGVHD and a more favorable toxicity profile. The higher severe aGVHD warrants further study to optimize this regimen. The trial was registered at www.clinicaltrials.gov as #NCT01951885.

1 January 2020 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
BNBrian T. Nguyen
Brian T. Nguyen
CVCaroline Violette
Caroline Violette
HLHong Li
Hong Li
JJJeffrey T. Jensen
Jeffrey T. Jensen
Nguyen BT, et al. World J Mens Health. 2019 Jan;37:e58. https://doi.org/10.5534/wjmh.190098

12 January 2026 in Neuro-Oncology Advances
Verified
Journal Article
Open access
ALAlyssa Lucas
Alyssa Lucas
DPDavid Peereboom
David Peereboom
YRYasmeen Rauf
Yasmeen Rauf
HLHong Li
Hong Li
JHJoshua Hanlon
Joshua Hanlon
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Background: Treatment options in progressive glioblastoma (GBM) are limited, especially in patients who have experienced disease progression while receiving bevacizumab therapy. This phase 2 study was conducted to evaluate the efficacy and safety of regorafenib monotherapy in patients with GBM. Methods: Eligible patients had radiographic progression of histologically confirmed GBM following second- or third-line bevacizumab therapy. They received regorafenib monotherapy using the dose escalation strategy demonstrated in the ReDOS phase 2 clinical trial evaluating regorafenib in metastatic colon cancer. The target dose was 160 mg once daily, administered for 3 weeks on/1 week off in 28-day cycles. Patients underwent brain magnetic resonance imaging (MRI) every 8 weeks and were assessed via modified Response Assessment in Neuro-Oncology criteria. Patients continued treatment with regorafenib therapy until they experienced progression or excessive toxicity. Results: Based on the analysis of 13 enrolled patients, there were no responses and 12 of 13 (92.3%) had progressive disease on brain MRI; 1 patient went off study due to an adverse event occurring before assessment. The median overall survival (OS) was 4.1 months (95% CI 2.0-7.3). The OS at 12 months was 23% (0.2-46). The PFS at both 3 and 6 months was 7.7% (0.0-22.2%) with a median PFS of 1.0 month, (0.4-1.8). There was a total of 14 Grade 3 or 4 AEs and no Grade 5 AEs. Conclusions: Regorafenib did not improve OS or PFS in bevacizumab-refractory recurrent glioblastoma. The study was halted early due to futility. Trial Registration: NCT04051606.

24 June 2026
Verified
Other
Open access
KFKarie Feldman
Karie Feldman
HLHong Li
Hong Li
DBDiana Basali
Diana Basali
FAFaiz Anwwer
Faiz Anwwer
KBKimberly Bell
Kimberly Bell
HHHeather McKee Hurwitz
Heather McKee Hurwitz
Participant demographic characteristics (N = 199).